Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05322577 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

A Phase 1 study of Gastric Cancer and Gastroesophageal-junction Cancer, sponsored by Amgen.

Active
Registry status
Phase 1
Development phase
72
Enrollment target
20
Study locations

NCT05322577 is a Phase 1 study of Gastric Cancer and Gastroesophageal-junction Cancer that is active but no longer recruiting, run by Amgen. The registered enrollment target is 72 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05322577, a Phase 1 study of Gastric Cancer and Gastroesophageal-junction Cancer, is active but no longer recruiting, sponsored by Amgen.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
72 participants
Enrollment target
20
Study locations

Study Summary

The main objectives of this study are to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies, and to evaluate the efficacy of bemarituzumab in combination with S-1 and oxaliplatin (SOX) and nivolumab as assessed by objective response.

Conditions Studied

Gastric Cancer Gastroesophageal-junction Cancer

Interventions

  • DRUG Nivolumab
  • DRUG CAPOX
  • DRUG Bemarituzumab
  • DRUG SOX

Study Locations (20)

Gifu

  • Gifu University Hospital - Gifu
  • Ogaki Municipal Hospital - Ogaki-shi

Gunma

  • Gunma University Hospital - Maebashi
  • Gunma Prefectural Cancer Center - Ota-shi

Hiroshima

  • Hiroshima City Hiroshima Citizens Hospital - Hiroshima
  • Hiroshima University Hospital - Hiroshima

Kanagawa

  • St Marianna University Hospital - Kawasaki-shi
  • Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center - Yokohama

New York

  • Northport Veterans Affairs Medical Center - Northport

Aichi-ken

  • Fujita Health University Hospital - Toyoake-shi

Aomori

  • Hirosaki University Hospital - Hirosaki-shi

Chiba

  • Chiba University Hospital - Chiba

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2022-05-17
Est. Completion 2026-08-12
Phase Phase 1

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05322577

The ClinicalTrials.gov registry entry for NCT05322577 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (77% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.

NCT05322577 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Gifu, Gunma, Hiroshima.

Frequently Asked Questions

What is clinical trial NCT05322577 about?

NCT05322577 is a clinical study titled "A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.". The main objectives of this study are to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies, and to evaluate the efficacy of bemarituzumab in combination with S-1 and oxaliplatin (SOX) and nivolumab as assessed by objective response.

What is the current status of trial NCT05322577?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2022-05-17. Estimated completion is 2026-08-12.

What conditions does trial NCT05322577 study?

This clinical trial studies the following conditions: Gastric Cancer, Gastroesophageal-junction Cancer.

What interventions are being tested in trial NCT05322577?

The interventions under investigation include: Nivolumab (DRUG), CAPOX (DRUG), Bemarituzumab (DRUG), SOX (DRUG).

Who is sponsoring clinical trial NCT05322577?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05322577 being conducted?

This trial has 20 study locations across New York, Aichi-ken, Aomori, Chiba, Ehime. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Gastroesophageal-junction Cancer

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.